Press Releases

Press Releases - Current

Press Releases - 2015

  December 23, 2014
CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments
  December 8, 2014
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites
  December 2, 2014
CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period
  November 3, 2014
CEL-SCI Enrolls 22 Patients during October in Its Phase III Immunotherapy Head and Neck Cancer Trial
  October 24, 2014
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million
  October 21, 2014
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
  October 21, 2014
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants
  October 20, 2014
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants
  October 3, 2014
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial
  September 29, 2014
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
  September 10, 2014
University of Minnesota Masonic Cancer Center Joins CEL-SCI's Phase III Head & Neck Cancer Trial
  September 3, 2014
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
  August 19, 2014
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada
  August 8, 2014
CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results
  August 1, 2014
CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled To Date in Its Phase III Head and Neck Cancer Trial
  July 30, 2014
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial
  July 22, 2014
CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey
  July 17, 2014
CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka
  July 15, 2014
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
  July 11, 2014
CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference
  July 8, 2014
CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI'S Phase III Head and Neck Cancer Trial into Austria
  July 1, 2014
CEL-SCI Reports 93% Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  June 18, 2014
CEL-SCI to Present at the 2014 BIO International Convention
  June 3, 2014
CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
  June 2, 2014
CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom
  May 27, 2014
University of Cincinnati Cancer Institute's Comprehensive Head and Neck Cancer Center Joins CEL-SCI's Phase III Trial
  May 13, 2014
CEL-SCI Corporation Reports Second Quarter Fiscal 2014 Financial Results
  May 1, 2014
CEL-SCI Reports April 2014 is another Record Month for Patient Enrollment in its Phase III Head and Neck Cancer Trial
  April 29, 2014
CEL-SCI Corporation Receives $3 Million from Warrant Exercises
  April 28, 2014
Southern Illinois University School of Medicine Becomes Clinical Site for CEL-SCI's Global Phase III Immunotherapy Head and Neck Cancer Trial
  April 22, 2014
CEL-SCI to Sponsor Symposium on Multikine at European Congress on Head & Neck Oncology 2014
  April 17, 2014
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $10 Million
  April 14, 2014
CEL-SCI Corporation Prices $10 Million Public Offering of Common Stock and Six Month Warrants
  April 11, 2014
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Six Month Warrants
  April 8, 2014
Henry Ford Health System of Detroit to Enroll and Treat Patients in CEL-SCI's Phase III Head and Neck Cancer Clinical Trial
  April 2, 2014
Arizona Cancer Research Alliance & 21st Century Oncology to Enroll Patients in CEL-SCI's Global Phase III Head and Neck Cancer Trial
  April 1, 2014
CEL-SCI Reports March 2014 is Record Month for Patient Enrollment in Phase III Head and Neck Cancer Trial
  March 4, 2014
First U.S. Clinical Site Opens for CEL-SCI'S Global Phase III Immunotherapy Head and Neck Cancer Trial Expansion
  February 27, 2014
CEL-SCI Reports 146 Patients Enrolled in its Phase III Immunotherapy Head and Neck Cancer Trial
  February 11, 2014
CEL-SCI Corporation Reports First Quarter 2014 Financial Results
  February 7, 2014
CEL-SCI to Present at 16th Annual BIO CEO & Investor Conference
  February 4, 2014
CEL-SCI Corporation Receives Approval for Listing and Trading of Warrants from the NYSE MKT under the Ticker Symbol "CVM WS"
  February 3, 2014
U.S. Navy Approves Start of CEL-SCI's Phase I Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
  January 23, 2014
CEL-SCI Receives Government Approval in Serbia to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
  January 2, 2014
CEL-SCI Reports Fiscal 2013 Financial Results and Clinical & Corporate Developments

Press Releases - 2013

Press Releases - 2012

Press Releases - 2011